A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
about
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down SyndromeDissecting Alzheimer disease in Down syndrome using mouse modelsSelectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase InhibitorsRoles of tau protein in health and disease.DYRK1A inhibition as potential treatment for Alzheimer's disease.Genetics of Frontotemporal Lobar Degeneration: From the Bench to the Clinic.Dyrk1 inhibition improves Alzheimer's disease-like pathology.Inhibition of DYRK1A disrupts neural lineage specification in human pluripotent stem cellsNeuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome.Increased levels of plasma total tau in adult Down syndrome.Tau Proteins and Tauopathies in Alzheimer's Disease.In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome.Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.A Requirement for Mena, an Actin Regulator, in Local mRNA Translation in Developing Neurons.Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations.Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tauDevelopment of Kinase Inhibitors via Metal-Catalyzed C⁻H Arylation of 8-Alkyl-thiazolo[5,4-]-quinazolin-9-ones Designed by Fragment-Growing StudiesCorrection of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A
P2860
Q26745413-1729BDC5-31ED-4B83-B2A3-B34F0BB644FEQ26777254-A660572F-C77F-4F05-A8B0-8C82E119AA32Q28546672-2D65437D-2524-49F8-B689-41A4B5D2FE51Q33559303-1F2FADBF-B95D-434A-8C56-982C74384D5FQ38807264-9ADFE9A0-B28D-48F8-B3C7-D4A3B931657EQ38814847-8E23FC3A-A610-4892-B75C-A3ABABA50C07Q41628814-1391A183-D4CA-4333-82A7-1903F8365461Q41918473-3C1373E2-E680-4D35-B72D-B23FD227A915Q46293399-D3E5C3FF-658F-4C5F-9E98-D04811B2CA68Q47143134-93EC2173-E3F7-4135-8761-49DB55ECB478Q47233523-9F60E75D-4277-4C35-8009-14F27B2D357DQ47319838-1A23B701-0EF7-46F3-8619-8ED7D49AA77DQ47753817-74CE4869-207F-4E58-AF8F-42684E54D21BQ48159615-BC4A96F6-591E-427D-B027-A1FDDE0C3833Q48175839-BC92AE9A-12C8-4673-A641-44C4F77E4212Q50307045-DF351B21-D35B-4696-ACB6-BE4FE1EF78A0Q50858078-D5B455D3-28C8-4105-9FC0-94D0075AAF5BQ56889147-AF7B341C-BF20-4B99-8B99-0A5136ECEC57Q58696298-ED13025E-F2C3-4490-82B6-E5532A91AB2BQ59127645-CF1D0477-CCC4-4E42-810E-932560EBB06B
P2860
A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A novel DYRK1A (dual specifici ...... amyloid pathologies in vitro.
@en
A novel DYRK1A
@nl
type
label
A novel DYRK1A (dual specifici ...... amyloid pathologies in vitro.
@en
A novel DYRK1A
@nl
prefLabel
A novel DYRK1A (dual specifici ...... amyloid pathologies in vitro.
@en
A novel DYRK1A
@nl
P2093
P2860
P921
P356
P1476
A novel DYRK1A (dual specifici ...... d amyloid pathologies in vitro
@en
P2093
Alicia Foucourt
Angélique Girard
Anne-Sophie Casagrande
Catherine de Oliveira
Hélène Benyamine
Laurence Delalonde
Laurent Désiré
Matthew P Pando
Séverine Coutadeur
Thierry Taverne
P2860
P304
P356
10.1111/JNC.13018
P407
P577
2015-01-26T00:00:00Z